Targazyme, Inc. a clinical-stage biopharmaceutical company developing enzyme technologies and products to improve efficacy outcomes for cancer immunotherapy and cell therapy, announced today the receipt of an SBIR award to fund its program for a novel cell-based restorative approach to treat diabetes-related retinopathy.
http://ift.tt/XlYsDr
http://ift.tt/XlYsDr
No comments:
Post a Comment